Literature DB >> 28832940

Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?

Valentín Ortiz-Maldonado1, Neus Villamor2,3, Tycho Baumann1,3, Marta Aymerich2,3, Laura Magnano2, Pablo Mozas1, Alfredo Rivas-Delgado1, Alejandra Martínez-Trillos1,3, Eva Giné1,3, Elías Campo2,3, Armando López-Guillermo1,3, Julio Delgado1,3.   

Abstract

Entities:  

Keywords:  hairy-cell leukaemia; immunophenotyping; minimal residual disease; purine analogues

Mesh：

Substances：

Year:  2017        PMID： 28832940     DOI： 10.1111/bjh.14900

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

Review 1.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

2.  Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia.

Authors:  Alessandro Broccoli; Carolina Terragna; Laura Nanni; Marina Martello; Silvia Armuzzi; Claudio Agostinelli; Alice Morigi; Beatrice Casadei; Cinzia Pellegrini; Vittorio Stefoni; Elena Sabattini; Lisa Argnani; Pier Luigi Zinzani
Journal:  Hematol Oncol       Date:  2021-10-15       Impact factor: 4.850

3.  Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.

Authors:  Dai Chihara; Evgeny Arons; Maryalice Stetler-Stevenson; Constance Yuan; Hao-Wei Wang; Hong Zhou; Mark Raffeld; Liqiang Xi; Seth M Steinberg; Julie Feurtado; Lacey James-Echenique; Chin-Hsien Tai; Keyur P Patel; Raul C Braylan; Katherine R Calvo; Irina Maric; Alina Dulau-Florea; Robert J Kreitman
Journal:  Blood Adv       Date:  2021-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.